J. Schultze

DCs in lymphoma--biology and therapeutic aspects.

M. von Bergwelt-Baildon, J. Schultze, F. Fiore, 2004, Cytotherapy.

The bi‐specific CD3 × NCAM antibody: a model to preactivate T cells prior to tumour cell lysis

F. Berthold, K. Ernestus, M. Klehr, 2003, Clinical and experimental immunology.

Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy.

A. Mackensen, A. Lindemann, R. Mertelsmann, 1994, Human gene therapy.

An integrated cell atlas of the human lung in health and disease

Malte D. Luecken, M. Krasnow, O. Rozenblatt-Rosen, 2022, bioRxiv.

CD40 activation: potential for specific immunotherapy in B-CLL.

J. Gribben, M. von Bergwelt-Baildon, B. Maecker, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour immunotherapy: new tools, new treatment modalities and new T‐cell antigens

K. Anderson, J. Schultze, M. von Bergwelt-Baildon, 2001, Vox sanguinis.

Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

K. Anderson, K. Anderson, L. Nadler, 2005, Clinical and Experimental Immunology.

A pilot study of combined immunotherapy with autologous adoptive tumour‐specific T‐cell transfer, vaccination with CD40‐activated malignant B cells and interleukin 2

J. Gribben, L. Nadler, J. Schultze, 2001, British journal of haematology.

Apoptosis-resistant phenotype of classical Hodgkin's lymphoma is not mediated by somatic mutations within genes encoding members of the death-inducing signaling complex (DISC)

R. Küppers, M. Hansmann, R. Schmitz, 2005, Leukemia.

Macrophages in human cancer: Current and future aspects

J. Schultze, Mallmann, S. Schmidt, 2012 .

New Antigens and Avenues to Immunotherapy of Cancer

J. Schultze, J. Schultze, 2003 .